Literature DB >> 12528692

Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

Heiko Braak1, Kelly Del Tredici, Hansjürgen Bratzke, John Hamm-Clement, Daniele Sandmann-Keil, Udo Rüb.   

Abstract

The synucleinopathy known as idiopathic Parkinson's disease (IPD) is a multi-system disorder in the course of which only a few predisposed nerve cell types in specific regions of the human brain become progressively involved. The underlying neuropathological process (formation of proteinaceous intraneuronal inclusion bodies) intracerebrally begins in clearly defined induction sites and advances in a topographically predictable sequence. Components of the autonomic, limbic, and motor systems sustain especially heavy damage. During the presymptomatic stages 1 and 2, the IPD-related inclusion body pathology remains confined to the medulla oblongata and olfactory bulb. In stages 3 and 4, the substantia nigra and other nuclear grays of the midbrain and basal forebrain are the focus of initially subtle and, then, severe changes. The illness reaches its symptomatic phase. In end-stages 5 and 6, the pathological process encroaches upon the telencephalic cortex. IPD manifests itself in all of its dimensions, which under the influence of the supervening cortical pathology are subject to increasing complexity.

Entities:  

Mesh:

Year:  2002        PMID: 12528692     DOI: 10.1007/s00415-002-1301-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  204 in total

1.  Retinal nerve changes in patients with tremor dominant and akinetic rigid Parkinson's disease.

Authors:  Mohammad Rohani; Arash Sefidkar Langroodi; Shadi Ghourchian; Khalil Ghasemi Falavarjani; Reza SoUdi; Gholamali Shahidi
Journal:  Neurol Sci       Date:  2012-06-03       Impact factor: 3.307

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Environmental neurotoxin-induced progressive model of parkinsonism in rats.

Authors:  Wei-Bin Shen; Kimberly A McDowell; Aubrey A Siebert; Sarah M Clark; Natalie V Dugger; Kimberly M Valentino; H A Jinnah; Carole Sztalryd; Paul S Fishman; Christopher A Shaw; M Samir Jafri; Paul J Yarowsky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

Review 4.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

5.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

6.  In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms.

Authors:  Valentina Arnao; Antonio Cinturino; Francesca Valentino; Valentina Perini; Sergio Mastrilli; Gabriele Bellavia; Giovanni Savettieri; Sabrina Realmuto; Marco D'Amelio
Journal:  Clin Auton Res       Date:  2015-09-10       Impact factor: 4.435

7.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

8.  Parkinson's Disease-Related Motor and Nonmotor Symptoms in the Lancaster Amish.

Authors:  Michael D F Goldenberg; Xuemei Huang; Honglei Chen; Lan Kong; Teodor T Postolache; John W Stiller; Katherine A Ryan; Mary Pavlovich; Toni I Pollin; Alan R Shuldiner; Richard B Mailman; Braxton D Mitchell
Journal:  Neuroepidemiology       Date:  2020-07-31       Impact factor: 3.282

9.  White matter microstructural integrity and executive function in Parkinson's disease.

Authors:  Catherine Gallagher; Brian Bell; Barbara Bendlin; Matthew Palotti; Ozioma Okonkwo; Aparna Sodhi; Rachel Wong; Laura Buyan-Dent; Sterling Johnson; Auriel Willette; Auriel Wilette; Sandra Harding; Nancy Ninman; Erik Kastman; Andrew Alexander
Journal:  J Int Neuropsychol Soc       Date:  2013-01-15       Impact factor: 2.892

10.  Reduced striatal tyrosine hydroxylase in incidental Lewy body disease.

Authors:  Thomas Gerald Beach; Charles H Adler; Lucia I Sue; Jeffrey B Peirce; Jyothi Bachalakuri; Jessica E Dalsing-Hernandez; Lih Fen Lue; John N Caviness; Donald J Connor; Marwan N Sabbagh; Douglas G Walker
Journal:  Acta Neuropathol       Date:  2007-11-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.